- Report
- July 2025
- 371 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Clinical Trials
- July 2025
- 220 Pages
Global
From €2659EUR$3,000USD£2,289GBP
Photodynamic therapy (PDT) is a minimally invasive treatment modality used in dermatology for various skin conditions, including precancerous lesions like actinic keratosis, as well as for certain types of skin cancer such as basal cell carcinoma and squamous cell carcinoma. PDT involves the application of a photosensitizing agent to the skin, which is then activated by a specific wavelength of light. This activation leads to the generation of reactive oxygen species that selectively target and destroy abnormal cells. Dermatological applications of PDT offer the advantage of targeting specific tissue sites while minimizing damage to surrounding healthy skin. The market has seen advancements in the development of more efficient photosensitizing agents and light delivery systems, catering to the demand for effective and patient-friendly therapeutic options. Additionally, ongoing research within the field is focused on enhancing the efficacy of PDT, extending its use to other dermatological conditions, and improving the cosmetic outcomes for patients.
Several companies are operational within the PDT market in dermatology. Some notable players include Biofrontera AG, which provides therapies for actinic keratosis and superficial skin cancer; Galderma, known for its range of dermatological treatments; Photocure ASA, specializing in bladder cancer and dermatology treatments; and DUSA Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries, which markets products for skin health conditions, including PDT treatments. Show Less Read more